GlaxoSmithKline CEO's reform-minded rep under fire in China probe

Was GlaxoSmithKline ($GSK) CEO Andrew Witty looking in the wrong direction when he pledged to clean up his company's act? As the Wall Street Journal reports, Witty has focused heavily on reforming the company's U.S. operations by resolving government investigations in process when he took over and putting new policies in place to prevent a repeat. But as the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have been rigorous enough. Report (sub. req.)

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.